Treatment of patients with keratoconjunctivitis sicca with Optive™: results of a multicenter, open-label observational study in Germany
Thomas Kaercher1, Patricia Buchholz2, Friedemann Kimmich31Augenarztpraxis, Heidelberg, Germany; 2Allergan Europe, Ettlingen, Germany; 3Eyecons, Pfinztal, GermanyObjective: To evaluate the efficacy and tolerability of OptiveTM, a new dry eye product containing sodium carboxymethylcellulose (0.5%) and...
Guardado en:
Autores principales: | Thomas Kaercher, Patricia Buchholz, Friedemann Kimmich |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/63120919cba7403bafb0e8d7c707075d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca
por: Koray Gumus, et al.
Publicado: (2008) -
Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
por: Dodi PL
Publicado: (2015) -
A prospective, multicenter, noninterventional study of Optive Plus® in the treatment of patients with dry eye: the prolipid study
por: Kaercher T, et al.
Publicado: (2014) -
A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
por: Jerkins GW, et al.
Publicado: (2020) -
Disruption of TGF-β signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca.
por: Cintia S De Paiva, et al.
Publicado: (2011)